[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350192-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-350192-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","interleukin-1-as-target-to-induce-synthetic-lethality-in-kras-mutant-biliary-tract-cancer","Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer","","Biliary tract cancer (BTC) often carries KRAS mutations linked to treatment resistance and poor prognosis, motivating KRAS-based synthetic lethality (SL) target discovery. The study used DepMap projects to predict KRAS synthetic-lethal genes and an FDA-approved anticancer drug library to identify effective compounds against KRAS-mutant BTC. Loss of GATA2 reduced KRAS-mutant BTC viability. Screening highlighted disulfiram, acting mainly by inhibiting IL-1β, with GATA2 transcriptionally enhancing IL-1β to drive NF-κB signaling. Results were validated in cell models and PDX, suggesting GATA2/IL-1β inhibition as therapy for KRAS-mutant BTC and possibly other KRAS cancers.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/interleukin-1-as-target-to-induce-synthetic-lethality-in-kras-mutant-biliary-tract-cancer/350192/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/interleukin-1-as-target-to-induce-synthetic-lethality-in-kras-mutant-biliary-tract-cancer/350192.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal regarding KRAS-mutant biliary tract cancer?","Question",{"text":63,"@type":64},"To identify and validate therapeutic targets of KRAS using a synthetic lethality strategy for treating biliary tract cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were synthetic lethal candidates and drugs identified?",{"text":68,"@type":64},"DepMap projects were used to predict KRAS synthetic-lethal genes, and an FDA-approved anticancer drug library was applied to screen candidate drugs effective against KRAS-mutant BTC.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism links GATA2, IL-1β, and KRAS-mutant BTC survival?",{"text":72,"@type":64},"GATA2 specifically enhances IL-1β transcription to promote NF-κB signaling; inhibiting IL-1β phenocopies GATA2 deficiency and reduces KRAS-mutant BTC viability.",{"name":74,"@type":61,"acceptedAnswer":75},"Are the synthetic lethal effects supported beyond cell lines?",{"text":76,"@type":64},"Yes. The IL-1β inhibition and GATA2-related synthetic lethal effects were confirmed using patient-derived xenografts (PDX), a KRAS oncogene-driven tumor model, and other KRAS-mutant cancer cell lines.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},350192,1790670374,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":112,"preview_page_count":33,"preview_urls":149},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","pISSN 2287-2728 eISSN 2287-285X  \nOriginal Article  \n[https://doi.org/10.3350/cmh.2025.1278](https://doi.org/10.3350/cmh.2025.1278)[ ](https://doi.org/10.3350/cmh.2025.1278)Clinical and Molecular Hepatology 2026;32:904-918  \nInterleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer  \nShijie Li1,2,3,*, Yukai Shan1,*, Tianen Chen1,*, Win Topatana1,2, Sarun Juengpanich1,2,3, Ziyi Lu1, Yuchao Sun1, Tianao Xie1, Ruijing Ruijing1, Lidan Hou1, Jiang Chen1, Guojun Chen1, Jiemin Lv1, Xianjue Ma4,5, Pengjuan Guo4,5, Dan Gabriel Duda6, Xiujun Cai1,2,3, and Mingyu Chen1,2,3,7  \n1Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University; 2School of Medicine, Zhejiang University; 3National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments, Sir Run-Run Shaw Hospital, Zhejiang University; 4 Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University; 5Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, China; 6Department of Surgery, Weill Medical College of Cornell University, Houston Methodist Academic Institute, Houston, TX, USA; 7State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, China  \nGraphical Abstract  \nStudy Highlights  \n• Transcription factor GATA2 has a synthetic lethal effect on KRAS-mutant BTC.  \n• Disulfiram, an FDA-approved drug, primarily exerts a synthetic lethal effect by inhibiting IL-1β in KRAS-mutant BTC.  \n• GATA2 specifically enhanced the transcription of IL-1β to promote NF-κB signaling for KRAS-mutant BTC survival.  \n• The synthetic lethal effect of inhibiting GATA2/IL1β could extend to other KRAS-mutant cancers.  \nCopyright © 2026 by Korean Association for the Study of the Liver  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nShijie Li, et al.  \nIL-1β as target to induce SL in KRAS mutant BTC  \nBackground/Aims: Biliary tract cancer (BTC) frequently harbors KRAS mutations, which are associated with resistance to traditional treatment and a poor prognosis. Synthetic lethality (SL) strategy may provide other targets of KRAS. Therefore, we aim to identify and validate potential therapeutic targets of KRAS for the treatment of BTC via SL. Methods: The dependency (DepMap) projects were used to predict the synthetic lethal gene of KRAS. FDAapproved anticancer drug library was applied to screen potential drugs effective against KRAS-mutant BTC. Furthermore, the synthetic lethal effects or corresponding mechanisms of potential genes and drugs on BTC were investigated using KRAS-mutant and KRAS-wild type BTC cell lines, patient-derived xenografts (PDX), and KRAS oncogene-driven tumor models, as well as other KRAS-mutant cancer cell lines.  \nResults: Initially, we discovered that the loss of GATA2 reduced the viability of KRAS-mutant but not KRAS-wildtype BTC. Subsequently, the drug library screened out disulfiram, which primarily exerts a synthetic lethal effect by inhibiting interleukin-1β (IL-1β) in KRAS-mutant BTC. Mechanistically, GATA2 specifically enhanced the transcription of IL-1β to promote NF-κB signaling in KRAS-mutant BTC. IL-1β inhibition phenocopied GATA2 deficiency, leading to reduced KRAS-mutant BTC viability. These synthetically lethal effects were confirmed using PDX, a KRAS oncogene-driven tumor model, as well as in other KRAS-mutant cancer cell lines.  \nConclusions: In summary, these results indicate that inhibiting GATA2/IL1β could be a therapeutic strategy in KRAS-mutant BTC and potentially other cancers. (Clin Mol Hepatol 2026;32:904-918)  \nKeywords: ","cbCaiqx3wwnFi2tf","https://ap.wps.com/l/cbCaiqx3wwnFi2tf","pdf",4106215,16,"English","# Introduction\n## Rationale and background on BTC and KRAS mutations\n## Synthetic lethality strategy and motivation\n# Methods\n## Computational prediction of KRAS SL genes (DepMap)\n## Drug library screening and experimental validation\n# Results\n## GATA2 loss selectively reduces KRAS-mutant BTC viability\n## Disulfiram identifies IL-1β inhibition as the primary SL mechanism\n## GATA2 drives IL-1β transcription and NF-κB signaling\n## Validation across PDX and additional KRAS-mutant models\n# Conclusions","[{\"question\":\"What is the study’s main goal regarding KRAS-mutant biliary tract cancer?\",\"answer\":\"To identify and validate therapeutic targets of KRAS using a synthetic lethality strategy for treating biliary tract cancer.\"},{\"question\":\"How were synthetic lethal candidates and drugs identified?\",\"answer\":\"DepMap projects were used to predict KRAS synthetic-lethal genes, and an FDA-approved anticancer drug library was applied to screen candidate drugs effective against KRAS-mutant BTC.\"},{\"question\":\"What mechanism links GATA2, IL-1β, and KRAS-mutant BTC survival?\",\"answer\":\"GATA2 specifically enhances IL-1β transcription to promote NF-κB signaling; inhibiting IL-1β phenocopies GATA2 deficiency and reduces KRAS-mutant BTC viability.\"},{\"question\":\"Are the synthetic lethal effects supported beyond cell lines?\",\"answer\":\"Yes. The IL-1β inhibition and GATA2-related synthetic lethal effects were confirmed using patient-derived xenografts (PDX), a KRAS oncogene-driven tumor model, and other KRAS-mutant cancer cell lines.\"}]","Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer | PDF",1790087633,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73973fa6b38c6a43d178bb26a77179a0.webp",983,1318,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b1a49fb890f19a0130b0de5ba3a25fd.webp",982,1309,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d27ecf1393a807f36fe4d8fef2ad1250.webp",981,1308,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46fe02a74bb45d879792b08718853a29.webp",980,1306]